C. Michael Gibson, M.D.

C. Michael Gibson, MD is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. The Baim institute was formerly known as Harvard Clinical Research Institute. The combined institutes have led over 1,250 studies, and 70 FDA submissions from their network of 26,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world’s most highly cited authors in all of science by Thomson Reuters. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack.

Dr. Gibson is currently leading the first large “Virtual” randomized trial which uses apps and the internet to eliminate “bricks and mortar” and is being conducted at 3% of the usual cost. The HEARTLINE trial of the Apple watch randomized 34,000 patients and is one of the largest randomized patient trials in cardiology history. Gibson is also leading several other AF trials currently.

Dr. Gibson has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology at Harvard Medical School affiliated hospitals and as a Vice Chairman of Medicine at a hospital of over 1,000 physicians.  For years, Gibson has been chosen as one of Boston’s Top Doctors & U.S. News & World Report also lists Gibson as one of America’s top doctors.